A collaborative decentralized science initiative known as Bio Protocol and the PeptAI platform have successfully utilized artificial intelligence to develop OX2R-004, a peptide aimed at potentially treating attention-deficit/hyperactivity disorder (ADHD), within a mere 24 hours. Research suggests that a deficiency of orexins, which are peptides synthesized in the hypothalamus, may play a role in ADHD. These amino acid chains are crucial for regulating the nervous system, circadian rhythms, and sleep-wake cycles. Currently, the available medications targeting orexin receptors function as antagonists, primarily prescribed for insomnia. In contrast, OX2R-004 has been engineered as an agonist, designed to activate the OX2R receptor. This peptide is intended to simulate the effects of natural orexin, potentially enhancing communication between different areas of the brain that are essential for maintaining focus. Notably, there are no approved orexin receptor agonists available in the market, and most ongoing clinical trials in this field concentrate on addressing issues related to excessive sleepiness and narcolepsy. While the advancements made with OX2R-004 are promising, it is important to note that this is still a preliminary computational model rather than a fully developed drug. The molecule requires further refinement as it degrades rapidly, may struggle to penetrate the blood-brain barrier, and could present unforeseen off-target effects. Nevertheless, the inclusion of machine learning tools was instrumental in predicting the peptide's structure, receptor interactions, toxicity, and additional factors, significantly accelerating the process that would have otherwise taken months to complete, all achieved in just one day.
Informational material. 18+.
